A few years ago I lectured in a European workshop about global risks. Before me lectured one of the World Health Organization (WHO) chief officers, who presented a very interesting graph.
What he showed was basically that life expectancy is expected to keep on rising all over the world, so that by the year 2100 it’s going to reach 85–90 years in high-income countries.
Well, I was pretty astounded about that forecast, which seemed to me extremely pessimistic. I talked with him over lunch, and asked whether this forecast included all of the technologies currently being developed in university labs. I asked how the forecasts would be affected by –
The development of nano-robots that could hold back cancer, coronary thrombosis (heart attack), strokes and other diseases from inside the body;
Sophisticated techniques for genetic engineering, that could produce vaccines against cancer and other diseases;
Tissue engineering techniques that could repair entire tissues – sometimes while they’re still in the body;
Artificial intelligence engines that would provide real-time medical monitoring and consultation much more accurate than that of today’s best medical doctors;
I’m paraphrasing his answer a little, since it all happened a few years ago, but the gist of what he said was –
“No, we can’t take all that into account. The model can’t acknowledge medical breakthroughs. We know that such breakthroughs will have a dramatic impact, but we just don’t know when they’ll emerge from the lab. But I can tell you that if even 15% of the research currently being done in biomedical labs succeeds, then the forecasts will change dramatically.”
So – there is simply no good forecast that will answer the basic question of how long we’re supposed to remain alive in this century. It is entirely conceivable – indeed, even likely, as that WHO official admitted – that sometime in the next few decades, a ‘perfect storm’ of medical breakthroughs will work together to dramatically halt aging and put a stop to most old-age diseases.
Somewhere in the world, in an undisclosed location, an individual is being genetically engineered right now in order to fulfill humanity’s long-time dream: to reverse biological aging, and become young again. The treatment is provided by BioViva, a small company with incredibly large dreams.
BioViva’s CEO, Elizabeth Parrish, announced that the treatment is composed of two different therapies, which have been developed and applied outside the USA. The patient is doing well at the moment, and will be routinely checked and evaluated, so that within twelve months we can expect some preliminary results.
I wrote a lot in the past about the future of radical longevity – i.e. extending the lifespan of ordinary human beings to a hundred years and more. The field excites me – and quite frankly, if you’re not exhilarated about any progress at all that happens in the field of life extension, then you must have completely managed to forget that you’re going to die someday from old age. Yeah, sorry about that.
I contacted Parrish and requested an interview, and she was kind enough to grant it, and to reveal a vision for humanity’s future that is truly radical and fascinating, but may well come true within the next few decades. It is a vision in which humanity largely eradicates old age and diseases, reaches equality between human beings and nations, and dares greatly in order to achieve greatness.
Disclaimer: I edited the quotes by Ms. Parrish for clarity.
Are They for Real?
After reading all the above, you would be justified asking: is Parrish and her company for real? Are they the real deal, doing actual science instead of general quackery?
While there is no way to know for sure, BioViva’s scientific advisory board contains some highly influential and prestigious scientists in the field of synthetic biology and longevity. It includes Prof. George Church from Harvard Medical School, who is one of the top experts in the world when it comes to genetic engineering. You can also find in there Dr. Aubrey de Grey – an advocate and a prophet of radical longevity.
The treatment enacted by BioViva, while still largely kept under wraps from the public, involves a combination of two different gene therapies: telomerase induction and myostatin inhibition. Telomerase controls the internal clock of each cell, and there’s evidence that myostatin inhibitors can reverse the accumulation of atherosclerotic plaques in veins. “We have that data in animals and in humans, but we need to run a clinical trial.” Says Parrish.
That is where the patient – the one receiving the combined therapy – comes into the picture. Apparently, he is a volunteer who has decided to sacrifice – or enhance – his body for science. While Parrish is reluctant to reveal his identity, she agreed to say that he’s in his 40s, and relatively healthy.
“We believe it is perfect because we could work with someone who was not in the worst stage of illness.” She explains.
The experiments are taking place outside the U.S. since “we didn’t want to deal with legal issues giving the treatment in the US, and it’s less expensive,” as Parrish puts it. If this sounds callous to you, you should know that many other pharmaceutical companies, including industry giants like Merck and Johnson & Johnson, are conducting their research outside the U.S. as well.
In general, Parrish isn’t holding much stock with the FDA and other governmental bodies that attempt to regulate medicine in the United States. “The first amendment protects your right over your body, to do with as you wish.” She states calmly. “I don’t think the government has a right to tell you what to do with your body, as long as it does not affect other people.”
And herein seems to lie one of the most interesting questions for the future of aging: assuming BioViva’s treatment strikes water and succeeds, the public will surely clamor for the new fountain of youth. Will governments worldwide be able to regulate it? Or will this become the great new illegal drug of the new century? At the moment, governments largely endorse medicine that is focuses on repairing the body. Will those governments be as happy to support human enhancement procedures?
“I think that what matters is the public demand, and the government will change its regulation according to public demand.” Says Parrish. And if the government doesn’t budge, then “a lot of people will go outside the country to get the treatment, and it may make some small countries very rich. Israel may become one of these countries, since it is very much ahead in research and very open to biotech. Another place is Japan, which has recently loosened its regulation on experimental medicine.”
The Future of Aging
So far, the medical sciences have mostly focused on repairing the damages being caused to the body over one’s lifetime. Parrish’s solution is much more radical and pro-active: she wants to hold back aging itself, since aging is correlated with so many other diseases. And she’s certain of success.
“The line between enhancement and preventative medicine will be blurry in the future.” She forecasts. “People will be taking gene therapy at younger and younger ages. This will probably be a twenty years process, but I believe that when you get to middle age, gene therapy will be given essentially as immunization to aging.”
This forecast, of course, partly relies on the current experiment having successful outcomes. Parrish is hopeful to see several different effects in the human patient, which include “outward markers like skin becoming youthful again, internal organs becoming healthy, increase in brain function and muscle mass, and better cardiovascular health.” All of the above effects were demonstrated in animal models, but never before in an experiment dedicated specifically to show that we can turn back biological aging.
Parrish expects to have preliminary results in the next twelve months. Until that happens, I take the chance to ask her what their next move will be, should the patient indeed regain some of his youth back. In that case, she says, BioViva would love to take this treatment through the FDA treatment approval process. But there is only one problem: “The FDA doesn’t consider aging as a disease.”
This is a mindset that Parrish has set out to change. Instead of trying to pop a pill for every different disease, we should go deeper and fix the aging process itself. “Every drug the FDA has passed, is still an experiment, and you’ll probably die – usually because of the disease the drug was supposed to take care of.” She says.
Parrish hopes that in twenty years they will get the costs down so that the average citizen would be able to pay for this treatment. “It’s cost effective,” she says, “because the US government is spending trillions for treating age-related diseases. So we hope it would get to everyone.”
As soon as the treatment becomes cheap enough, she will be the first to give it a shot. “I am 44, and I would say I have a chance to enjoy this treatment myself. I would absolutely take it right now, and my whole team would (our medical advisor has undergone the myostatin inhibition treatment five years ago), but the costs of the therapeutic are very high.”
It is almost certain that BioViva’s treatment will fail in the short run. Virtually no experiment in biology or in medicine ever works out the way it should for the first time, and there’s no reason to believe that BioViva’s treatment will be any different. However, we should not view this experiment as a one-time effort, but as one of the cobblestones in the path ahead.
The convictions upon which Parrish makes her case rely on the right of the individual over his or her body, the disillusionment with the power of the government to decide what’s best for the citizen, and moreover – on the realization that we can fix nature and reprogram our body as we desire. And in her words, as they are quoted in the BioViva site: “we want to make you smarter, stronger, faster and more visually accurate, and I think that is a good thing.”